⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563565 | 1.00 | — | — | |
| SCHEMBL2570646 | 1.00 | — | — | |
| SCHEMBL636305 | 0.73 | — | — | |
| SCHEMBL16312548 | 0.73 | — | — | |
| SCHEMBL12696702 | 0.73 | — | — | |
| SCHEMBL294878 | 0.73 | — | — | |
| SCHEMBL4107937 | 0.73 | — | — | |
| SCHEMBL1136114 | 0.73 | — | — | |
| SCHEMBL5354435 | 0.71 | — | — | |
| SCHEMBL3056738 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2690101-B1 | 5-Anilinoimidazopyridines and Methods of Use | GENENTECH INC (US) | 2015-06-24 | — | — | EP | claimed |
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | claimed |
| EP-2690101-A1 | 5-Anilinoimidazopyridines and Methods of Use | Genentech, Inc. (US) | 2014-01-29 | — | — | EP | claimed |
| EP-2222675-B1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH INC (US) | 2013-09-11 | — | — | EP | claimed |
| US-20120309765-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2012-12-06 | — | — | US | claimed |
| US-8293763-B2 | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents | GENENTECH, INC. (US) | 2012-10-23 | — | — | US | claimed |
| US-8288408-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | claimed |
| EP-2069354-B1 | Aza-benzofuranyl compounds and methods of use | GENENTECH INC (US) | 2011-11-02 | — | — | EP | claimed |
| US-20110158990-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-06-30 | — | — | US | claimed |
| US-10946093-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10646567-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3563870-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| EP-3169361-B1 | COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-2739358-B1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-11-28 | — | — | EP | disclosed |
| WO-2010003025-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENENTECH, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2099796-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009085983-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |